Condition
Diabetes Mellitus, Type 2
Locations
Canada, Germany
Start date
15/08/2025
Identifiers
Trial ID NN1436-7727,
NCT number NCT07112339,
Eudract number Not Available
NCT number NCT07112339,
Eudract number Not Available
Summary
This study compares insulin icodec, taken once a week, with other basal insulins, taken once a day, in people with type 2 diabetes.The purpose of this study is to see how well the approved injectable weekly insulin icodec maintains blood sugar levels when compared to approved and available daily injectable basal insulins in people with type 2 diabetes. The participants will either be prescribed weekly insulin icodec or a daily basal insulin (insulin glargine, insulin detemir or insulin degludec) based on current standards for the treatment of type 2 diabetes. The study will last for about 13 months.
Trial Overview:
Treatment
DRUG: Insulin icodec
DRUG: Basal insulin analogues
Study type
INTERVENTIONAL
Trial duration
Aug 15 2025 - Aug 31 2028
Participants
586
Phase
IIII
Are you eligible?
Gender
Male and female
Age
18 years and older
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.